AGIOS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AGIOS PHARMACEUTICALS, INC. | ||
| February 15, 2024 | By: | /s/ Brian Goff |
|---|---|---|
| Brian GoffChief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Brian Goff | Chief Executive Officer(Principal executive officer) | February 15, 2024 |
| Brian Goff | ||
| /s/ Cecilia Jones | Chief Financial Officer(Principal financial officer) | February 15, 2024 |
| Cecilia Jones | ||
| /s/ T.J. Washburn | Vice President, Controller(Principal accounting officer) | February 15, 2024 |
| T.J. Washburn | ||
| /s/ Jacqualyn A. Fouse | Chair of the Board of Directors | February 15, 2024 |
| Jacqualyn A. Fouse, Ph.D. | ||
| /s/ Rahul Ballal | Director | February 15, 2024 |
| Rahul Ballal, Ph.D. | ||
| /s/ Jeffrey Capello | Director | February 15, 2024 |
| Jeffrey Capello | ||
| /s/ Kaye Foster | Director | February 15, 2024 |
| Kaye Foster | ||
| /s/ Maykin Ho | Director | February 15, 2024 |
| Maykin Ho, Ph.D. | ||
| /s/ Catherine Owen | Director | February 15, 2024 |
| Catherine Owen | ||
| /s/ David Scadden | Director | February 15, 2024 |
| David Scadden, M.D. | ||
| /s/ David P. Schenkein | Director | February 15, 2024 |
| David P. Schenkein, M.D. | ||
| /s/ Cynthia Smith | Director | February 15, 2024 |
| Cynthia Smith | ||
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 2 |
|---|---|
| Consolidated Balance Sheets | 4 |
| Consolidated Statements of Operations | 5 |
| Consolidated Statements of Comprehensive (Loss) Income | 6 |
| Consolidated Statements of Stockholders’ Equity | 7 |
| Consolidated Statements of Cash Flows | 8 |
| Notes to Consolidated Financial Statements | 9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.